Protagenic Therapeutics, Inc.\new (PTIX) Total liabilities 2017–2026
Protagenic Therapeutics, Inc.\new (PTIX) total liabilities at each fiscal year-end, per SEC filings.
$1.0MFY2026 · since FY2017: $684,857 → $1.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $1.0M | -79.5% |
| FY2025 | $5.0M | +669.5% |
| FY2024 | $655,252 | -41.5% |
| FY2023 | $1.1M | +0.2% |
| FY2022 | $1.1M | -44.9% |
| FY2021 | $2.0M | — |
| FY2017 | $684,857 | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More PTIX financial trends
PTIX RevenuePTIX Net incomePTIX Net marginPTIX Gross profitPTIX Gross marginPTIX Operating incomePTIX Operating marginPTIX Operating cash flowPTIX Free cash flowPTIX Capital expendituresPTIX Return on equityPTIX Stock buybacksPTIX Dividends paidPTIX Total assetsPTIX Shareholders’ equityPTIX overview →